The observation that the three KMT2A-MLLT3+ cell lines displayed higher p18INK4C levels than the KMT2A-AFF1+ cell line supports the human RNA sequencing data showing that AML patient cells harbouring KMT2A-MLLT3 have higher CDKN2C p18INK4C expression than the pool of different KMT2A rearranged AML patient cells (Figure 1A). This evidence concerns the gene KMT2A and acute myeloid leukemia.